4-(2-Methoxypropan-2-yl)piperidine → 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine
반응식
[CH3:1][O:2][C:3]([CH:6]1[CH2:11][CH2:10][NH:9][CH2:8][CH2:7]1)([CH3:5])[CH3:4].Br[CH2:13][C:14]1[N:15]([CH3:30])[C:16]2[C:21]([N:22]=1)=[C:20]([N:23]1[CH2:28][CH2:27][O:26][CH2:25][CH2:24]1)[N:19]=[C:18]([Cl:29])[N:17]=2>>[Cl:29][C:18]1[N:17]=[C:16]2[C:21]([N:22]=[C:14]([CH2:13][N:9]3[CH2:10][CH2:11][CH:6]([C:3]([O:2][CH3:1])([CH3:5])[CH3:4])[CH2:7][CH2:8]3)[N:15]2[CH3:30])=[C:20]([N:23]2[CH2:24][CH2:25][O:26][CH2:27][CH2:28]2)[N:19]=1참가 물질
3
실험 절차
4-(2-methoxypropan-2-yl)piperidine (0.12 g) was reacted with 4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (0.25 g) via General Procedure E to give 300 mg of crude 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine, of which 0.78 g was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine via General Procedure A to yield 12 mg of 155 as a white solid following reverse phase purification. MS (Q1) 531.3 (M)+
출처 및 근거
- ORD 기록
- ord-43531e957de145a883e8d33acaaa3ee2
- 출처 데이터셋
- uspto-grants-2012_05
- 특허 번호
- US08173650B2
반응 노트
불러오는 중…